BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35471979)

  • 1. The diagnostic contribution of magnetic resonance imaging in the detection of axillary metastasis after neoadjuvant chemotherapy.
    İriağaç Y; Karaboyun K; Çavdar E; Avci O; Kurtoğlu Özçağlayan Tİ; Öznur M; Ozkan Gurdal S; Şeber ES
    Neoplasma; 2022 May; 69(3):741-746. PubMed ID: 35471979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
    Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
    JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axillary lymph node recurrence following wire-directed sentinel lymph node dissection for breast cancer patients with biopsy-proven axillary metastases prior to neoadjuvant chemotherapy at a safety net medical center.
    Sargent RE; Siegel E; Ito F; Kramme K; Kraft E; Hendrix V; Carr AA; Nelson ME; Bian SX; Jayachandran P; Sener SF
    J Surg Oncol; 2023 Jul; 128(1):9-15. PubMed ID: 36933187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
    Caudle AS; Yang WT; Krishnamurthy S; Mittendorf EA; Black DM; Gilcrease MZ; Bedrosian I; Hobbs BP; DeSnyder SM; Hwang RF; Adrada BE; Shaitelman SF; Chavez-MacGregor M; Smith BD; Candelaria RP; Babiera GV; Dogan BE; Santiago L; Hunt KK; Kuerer HM
    J Clin Oncol; 2016 Apr; 34(10):1072-8. PubMed ID: 26811528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of ultrasound in the clinical re-staging of the axilla after neoadjuvant chemotherapy (NACT).
    Peppe A; Wilson R; Pope R; Downey K; Rusby J
    Breast; 2017 Oct; 35():104-108. PubMed ID: 28704697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axillary ultrasonography combined with pre-operative wire localisation of clipped node in nodal restaging after neoadjuvant chemotherapy in node positive breast cancer patients: a pilot study.
    Pulappadi VP; Paul S; Hari S; Dhamija E; Manchanda S; Kataria K; Mathur S; Mani K; Gogia A; Deo S
    Br J Radiol; 2021 Nov; 94(1127):20210788. PubMed ID: 34491822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of axillary ultrasound (AUS) to assess the nodal status after neoadjuvant chemotherapy (NACT) in primary breast cancer patients.
    Leinert E; Lukac S; Schwentner L; Coenen A; Fink V; Veselinovic K; Dayan D; Janni W; Friedl TWP
    Surg Oncol; 2024 Feb; 52():102016. PubMed ID: 38056112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma.
    Nason KS; Anderson BO; Byrd DR; Dunnwald LK; Eary JF; Mankoff DA; Livingston R; Schmidt RA; Jewell KD; Yeung RS; Moe RE
    Cancer; 2000 Dec; 89(11):2187-94. PubMed ID: 11147588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axillary ultrasound after neoadjuvant therapy reduces the false-negative rate of sentinel lymph node biopsy in patients with cytologically node-positive breast cancer.
    Liu Y; Wang Y; Feng S; Xu Z; Yao M; Huang X; Li P; Wu L; Liu C; Chen X; Liang C; Liu Z
    Breast Cancer Res Treat; 2023 Feb; 197(3):515-523. PubMed ID: 36513955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy of magnetic resonance imaging to evaluate axillary lymph node status in breast cancer patients receiving neoadjuvant chemotherapy.
    Bansal GJ; Jaipal A; Wu GKC; Syed A
    Br J Radiol; 2023 Mar; 96(1143):20220904. PubMed ID: 36607272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Definitive results.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2021 Sep; 38():101636. PubMed ID: 34303211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of sentinel node biopsy in early breast cancer after neo-adjuvant chemotherapy: A prospective study.
    Najim O; Dockx Y; Huyghe I; van den Wyngaert T; Papadimitriou K; Tjalma WAA; Huizing MT
    Eur J Obstet Gynecol Reprod Biol; 2018 Oct; 229():108-111. PubMed ID: 30145524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of blue dye alone for sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initially node-positive breast cancer.
    Cavalcante FP; Zerwes FP; Souza ABA; Ziegelmann PK; Alcantara R; Cardoso A; Mattar A; Millen EC; Frasson AL
    Eur J Surg Oncol; 2024 Mar; 50(3):107967. PubMed ID: 38262300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.
    Schwartz GF; Tannebaum JE; Jernigan AM; Palazzo JP
    Cancer; 2010 Mar; 116(5):1243-51. PubMed ID: 20087958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy in patients with breast cancer: Does response in the breast predict axillary node response?
    Morgan C; Stringfellow TD; Rolph R; Kovacs T; Kothari A; Pinder SE; Hamed H; Sever AR
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):522-526. PubMed ID: 31740186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
    Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
    JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Preliminary results.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2019 Sep; 30():52-57. PubMed ID: 31500785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "This house believes that: Sentinel node biopsy alone is better than TAD after NACT for cN+ patients".
    Galimberti V; Ribeiro Fontana SK; Vicini E; Morigi C; Sargenti M; Corso G; Magnoni F; Intra M; Veronesi P
    Breast; 2023 Feb; 67():21-25. PubMed ID: 36566690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biopsy method and excision volume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer.
    Haigh PI; Hansen NM; Qi K; Giuliano AE
    Ann Surg Oncol; 2000; 7(1):21-7. PubMed ID: 10674444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.